Biokier
  • About
    • Our Approach
    • Our Management
    • Our Partners
    • Our Advisors
  • Technology & Results
    • BioKier Technology Overview
    • Potential Additional Uses of BioKier’s Product
    • Results to Date
    • Formulation
    • News
  • Links
  • Contact Us
Select Page

Results of 4-week BKR-017 study in type 2 diabetes subjects and ongoing activity

by BioKier | Apr 30, 2022 | Recent News

Despite significant delays related to COVID-19, in late 2020 BioKier completed a 4-week study of BKR-017 (orally administered colon-targeted, sustained-release 500 mg butyrate tablets) in type 2 diabetes (T2D) subjects. Dr. Kishore Gadde’s team at Pennington...

Completion of 4-week BKR-017 study in type 2 diabetes subjects and upcoming plans

by BioKier | Jan 26, 2021 | Recent News

Despite significant delays related to COVID-19, in late 2020 BioKier completed a 4-week study of BKR-017 in type 2 diabetes subjects. Dr. Kishore Gadde’s team at Pennington Biomedical Research Center (PBRC) successfully recruited and enrolled 14 subjects in the study....

JDRF Awarded Grant to Conduct Study of BioKier Product, Butyrate Tablet, BKR-017, in Type 1 Diabetes Patients

by BioKier | Oct 1, 2019 | Recent News

Mayo Clinic in Rochester MN  working together with BioKier, Inc. have been awarded a $386,760 SRA Grant by JDRF (formerly known as the Juvenile Diabetes Research Foundation) to Conduct a study in Type 1 Diabetes Patients. Adrian Vella MD (Mayo clinic, Rochester, MN)...

BioKier Awarded $3.0 million Phase IIb Small Business Innovation Research Grant

by BioKier | Oct 1, 2019 | Recent News

BioKier has been awarded a $3.0 million Phase IIb Small Business Innovation Research (SBIR) Grant by The National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), an institute of The National Institutes of Health (NIH). The grant will fund $1 million...

BioKier completes four-week clinical study with BKR-013 at Pennington Biomedical Research Center, Baton Rouge, LA.

by BioKier | Oct 1, 2019 | Recent News

BioKier completed a four-week clinical study with BKR-013 (L-glutamine in colon-targeted, sustained-release capsules) in Type 2 diabetes patients, who were already being treated with approved anti-diabetes drugs. This study was supported by an NIH SBIR grant. Fourteen...
« Older Entries

Copyright © 2020, BioKier, Inc. All Rights Reserved.